• News
  • SAN DIEGO
  • BioTech

Isis begins study for cardiovascular disease treatment

Carlsbad-based Isis Pharmaceuticals Inc. (Nasdaq: ISIS) has initiated a Phase 1 clinical study for an anti-sense drug targeting angiopoietin-like 3 protein (ANGPTL3), an independent risk factor for cardiovascular disease.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
42.37
  1.89  
+ 4.67%
2,369,672,000
62.66
22.25

Insider Trade Data

Date Insider Shares Type Value
10/17/2014 Isis Pharmaceuticals Inc 12,100 Sell $483,939
10/03/2014 Crooke, Stanley T 36,000 Sell $1,386,860
10/03/2014 Crooke, Stanley T 36,000 Exchange $507,630
10/03/2014 Isis, Pharmaceuticals Inc 10,300 Sell $394,118
10/03/2014 Isis Pharmaceuticals Inc 10,300 Sell $394,118

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chief Executive Officer, Founder, President, Chairman

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Subscribe Today!